Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 10, 2024
Discovery & Translation
Science Spotlight: As miRNAs get Nobel Prize, targeting advances continue
BioCentury’s roundup of translational innovation also features Vedanta’s solution to GI infection, Takeda’s exon-skipping delivery tech, and more
BioCentury | Jul 29, 2023
Discovery & Translation
Turning cancer drivers into cell death drivers; plus LNPs to edit stem cells and more
BioCentury’s roundup of translational innovations
BioCentury | Apr 25, 2023
Discovery & Translation
Prime and base editing for blood disorders, mutation tracing for NASH target discovery and more
BioCentury’s roundup of translational news
BioCentury | Jan 16, 2021
Translation in Brief
Dyne’s POC myotonic dystrophy data; plus pulmonary T cell subset contributes to local antibody production after reinfection, DiosCURE’s COVID candidates and more
BioCentury’s roundup of translational news
BioCentury | Nov 14, 2019
Emerging Company Profile
Cedilla: degrading proteins by modulating protein stability
How Cedilla harnesses native destabilization mechanisms to degrade proteins
BioCentury | Mar 15, 2019
Product Development
Fresh AIMMs for elite responders
AIMM's elite responder platform points to modified protein antigens in cancer
BioCentury | Apr 10, 2018
Preclinical News
Researchers identify coding, non-coding driver mutations in MM
Items per page:
1 - 10 of 19